

# Structured Medication Reviews on NHS Pathways

**Steve Moore**  
**Locality Medicines Manager**

**November 28<sup>th</sup> 2023**



# What is an SMR?

Structured Medicine Reviews (SMRs) are an evidence-based and comprehensive review of a patient's medication, taking into consideration all aspects of their health. In a structured medication review clinicians and patients work as equal partners to understand the balance between the benefits and risks of and alternatives of taking medicines. The shared decision-making conversation being led by the patient's individual needs, preferences and circumstances.

- **Key components of a SMR**
- Shared decision-making principles should underpin the conversation
- **Personalised approach** – tailored to the patient
- **Safety** – consider the balance of benefit and risk of current treatment and starting new medicines
- **Effectiveness** – all medication must be effective, noting NHS guidance on certain exceptions to items that should not routinely be prescribed in primary care.”

# What is NHS Pathways?

- Software we use through the Eclipse Live platform to analyse and risk stratify patients based on data extracted from the GP clinical system (emis)
- Same system that generates the red and amber patient safety alerts
- Anyone authorised can have an account to look at their own practice data
- <https://secure.nhspathways.org/>
- Get one time PIN
- ....and off you go



Network Contract Directed Enhanced  
Service

# Structured medication reviews and medicines optimisation: guidance

17 September 2020

# Who are the focus?

From 1 October 2020, each PCN must use appropriate tools to identify and prioritise patients who would benefit from a SMR, which must include those:

1. in care homes
2. with complex and problematic polypharmacy, specifically those on 10 or more medications
3. on medicines commonly associated with medication errors<sup>10</sup>
4. with severe frailty<sup>11</sup> who are particularly isolated or housebound or who have had recent hospital admissions and/or falls
5. using potentially addictive pain management medication.

10 See NHS Business Services Authority (2019) Medication safety – indicators specification <https://www.nhsbsa.nhs.uk/sites/default/files/2019-08/Medication%20Safety%20-%20Indicators%20Specification%20%28Aug19%29.pdf>

11 Based on the validation of the eFI, on average around 3% of over 65s will be identified as potentially living with severe frailty. However, this percentage may be significantly higher in some practices. Severe frailty is defined as a person having an eFI score of >0.36. <https://www.england.nhs.uk/ourwork/clinical-policy/olderpeople/frailty/efi/>

## Advice & Guidance

NHS Digital Assured

logged in as Steve

Logout

User Details

Change Password

Settings

Admin

Help

### SMR Quick Search

Patient ref:

Patient Code:

You can  
enter emis  
number here

Click here



Please Select Pathway of Choice



Diabetes



Eclipse Live



Eclipse QIC



SMRLive



Other

# Video and written guidance available

[NHS Pathways](#) | [SMR Home](#)

## SMR Quick Search

Patient ref:

Patient Code:

Home

Data Quality Status: ● Extractions up to date

## SMR Live Introductory Video

We are pleased to release the initial version of the SMR Live module. This is version 1.0 and we would appreciate all feedback for additional requirements.

[Click here to watch our introduction video](#)

[Click here to view the SMR Live user guide](#)

[Click here to view the Structured medication reviews specification guidance 2023-24 pdf](#)



# National medicines optimisation opportunities 2023/24

This is a supplementary support tool to be utilised in conjunction with your core clinical software.



Carbon Optimisation



Polypharmacy



Deprescribing



Antimicrobials



Dependency



Investment and Impact Fund 2023/24



SMR Case Load



Priority SMRs



**All SMR Pathways**



Care Home



High Risk Drugs



Medication Related Indicators



Frailty



Addiction



Pincer



Recent Admissions



STOMP



RADAR Alerts



Investment and Impact Fund 22/23



# A sample of pathways

	Anticholinergic Score >= 4	717 2.4%	4 / 4 8 / 5	0.0% 0/717 1 / 38	-	<a href="#">View</a>
	Polypharmacy (>10 Meds)	850 2.9%	5 / 4 30 / 26	0.0% 0/850 1 / 38	-	<a href="#">View</a>
	Pregabalin	241 0.8%	1 / 1 2 / 1	0.0% 0/241 1 / 38	-	<a href="#">View</a>
	Care Home	416 1.4%	1 / 1 4 / 4	0.0% 0/416 1 / 38	-	<a href="#">View</a>
	Inhaled LABA without ICS	2 0.0%	0 / 0 0 / 0	0.0% 0/2 1 / 38	-	<a href="#">View</a>
	Severe Frailty	374 1.3%	1 / 1 8 / 6	0.0% 0/374 1 / 38	-	<a href="#">View</a>
	Learning Disability or Autism on Psychotropic drug	134 0.5%	0 / 0 0 / 0	0.0% 0/134 1 / 38	-	<a href="#">View</a>

# National medicines optimisation opportunities 2023/24

This is a supplementary support tool to be utilised in conjunction with your core clinical software.



Carbon Optimisation




Polypharmacy



Deprescribing



Antimicrobials




Dependency



Investment and Impact Fund 2023/24



SMR Case Load



Priority SMRs



**All SMR Pathways**




Care Home




High Risk Drugs



Medication Related Indicators



Frailty



Addiction



Pincer



Recent Admissions



STOMP



RADAR Alerts



Investment and Impact Fund 22/23

Too scary!

Stick with list for now!

Filters: *None*Core20PLUS5 Filter  **reset****Age / Gender**

- Age 0-17
- Age 18-40
- Age 41-60
- Age 61-80
- Age over 80
- Age 65 and over
- Age 18 and over
- Age 18-60
- All Ages
- Male
- Female
- All Genders

**Smoker**

- Current Smokers
- Ex-Smoker
- Current Non-Smoker
- Smoking status not recorded
- All smoking statuses

**Core20 = DD 1-2**

- Deprivation Decile 1-2
- Deprivation Decile 1-4
- Deprivation Decile > 4
- All Deprivation Deciles

**BMI**

- BMI >27.5 to 35
- BMI >35 to 40
- BMI >40 to 50
- BMI > 50
- All BMIs

**Estimated Qrisk3 score**

- Estimated QRISK <=10%
- Estimated QRISK3 Score >10%
- Estimated QRISK3 Score >20%
- Estimated QRISK3 Score >25%
- Estimated QRISK3 Score >30%
- All QRISK3 Scores

**PLUS**

- White
- Asian
- Black
- Ethnicity Unknown
- All Ethnicities
- Learning Disability
- Severe Mental Illness
- Moderate/Severe Frailty
- Dementia
- Palliative Care
- Depression
- In Care Home
- On Antipsychotics
- On Gabapentinoids
- On Benzodiazepine or Z-drug
- On Benzodiazepine
- On Z-drug
- On Opiates

**Vaccinations**

- Flu vaccination
- No flu vaccination
- All patients
- Pneumococcal vaccine (last 5 yrs)
- No Pneumococcal vaccine (last 5 yrs)
- All patients
- Health Check**
- NHS Health Check (last 5 yrs)
- No NHS Health Check (last 5 yrs)
- All patients
- PRISM EA**
- High risk
- Medium risk
- Low risk
- No Activity
- All patients

Apply Filters

## ACB Score: 5

### Medication

### ACB Score

Amitriptyline

3



Furosemide (Frusemide) Tablets

1



Metoclopramide


1










# Choose a pathway



Dependency




Prescribing Pathway	Prevalence	Alerts	Patient Engagement	Rating	
 Pregabalin	<b>241</b> 0.8%	<b>1 / 1</b> 2 / 1	<b>0.0%</b> 0/241 1 / 38	-	<a href="#">View</a>
 Gabapentin	<b>259</b> 0.9%	<b>0 / 0</b> 4 / 4	<b>0.0%</b> 0/259 1 / 38	-	<a href="#">View</a>
 Opiates	<b>380</b> 1.3%	<b>1 / 0</b> 5 / 5	<b>0.0%</b> 0/380 1 / 38	-	<a href="#">View</a>
 Z-drug	<b>188</b> 0.6%	<b>1 / 1</b> 0 / 0	<b>0.0%</b> 0/188 1 / 38	-	<a href="#">View</a>
 Benzodiazepine	<b>258</b> 0.9%	<b>0 / 0</b> 3 / 2	<b>0.0%</b> 0/258 1 / 38	-	<a href="#">View</a>
 Smoking Protect	<b>4,098</b> 14.0%	<b>1 / 1</b> 12 / 10	<b>0.0%</b> 0/4,098 1 / 38	-	<a href="#">View</a>
 High Alcohol Intake	<b>173</b> 0.6%	<b>0 / 0</b> 1 / 0	<b>0.0%</b> 0/173 1 / 38	-	<a href="#">View</a>

### Patient Engagement Breakdown (Completed Questionnaire)




● Not Engaged

### SMR completed Breakdown (Patients Reviewed in last 12M)



● Reviewed ● Not Reviewed



Patient Count:  
**188**



**1 / 0** Alerts

Rank 1

**0 / 188**

Patient Engagement

Current QOF year

**33 / 188**

Last 12 Months

**57 / 188**

SMR Medication  
Reviews Completed

Rank 1

**0.00**

Admissions per patient

A&E

Rank 1

**0.00**

Admissions per patient

APC


### Comparison Charts [Nov 23]

Full list

Priority list



Safety Alerts



Patients
















Priority Patients

# Z-drug

Filters: None

Core20PLUS5 Filter 



















	Total Patients (Z-drug)	Total Patients in cohort	% Patients in cohort	
 Moderate / Severe Frailty	187	23	12.3%	<a href="#">View</a>
 Patients with morbid obesity (BMI>=40 or diabetes and BMI>=35)	187	11	5.88%	<a href="#">View</a>
 Current Smokers	187	39	20.86%	<a href="#">View</a>
 High Alcohol intake, >= 49 units per week	187	1	0.53%	<a href="#">View</a>
 Haemoglobin < 11	187	14	7.49%	<a href="#">View</a>
 Hyponatremia (<131)	187	3	1.6%	<a href="#">View</a>
 Polypharmacy (>10 meds)	187	42	22.46%	<a href="#">View</a>
 Patients with SMR Risk Score between 10 and 25	187	65	34.76%	<a href="#">View</a>
 Patients with SMR Risk Score > 25	187	4	2.14%	<a href="#">View</a>
 SMR: Patients with an Anticholinergic Score >= 4	187	40	21.39%	<a href="#">View</a>
 Patient in 3 SMR pathways	187	37	19.79%	<a href="#">View</a>
 Patient in 4 SMR pathways	187	18	9.63%	<a href="#">View</a>
 Patient in 5 or more SMR pathways	187	19	10.16%	<a href="#">View</a>



# Our Eclipse alerts

	Cardiovascular	Prescribing Safety Indicators	<p><b>Combined ACEI and ARB treatment</b></p> <p>MHRA warning-Combination use of medicines from different classes of renin-angiotensin system blocking agents: risk of hyperkalaemia, hypotension, and impaired renal function. <a href="https://www.gov.uk/drug-safety-update/combination-use-of-medicines-from-different-classes-of-renin-angiotensin-system-blocking-agents-risk-of-hyperkalaemia-hypotension-and-impaired-renal-function-new-warnings">https://www.gov.uk/drug-safety-update/combination-use-of-medicines-from-different-classes-of-renin-angiotensin-system-blocking-agents-risk-of-hyperkalaemia-hypotension-and-impaired-renal-function-new-warnings</a></p>	26/11/2023	<b>177</b>	<b>9</b>	<a href="#">View</a> <a href="#">Run</a> <a href="#">Edit</a> <a href="#">Delete</a>
	Dementia	Prescribing Safety Indicators	<p><b>Dementia patients taking antipsychotic medication with no indication</b></p> <p>Increased risk of cardiovascular events and death. Should be used only after thorough review and for shortest possible time. Review regularly. Only risperidone is licensed in this condition for a maximum of 6 weeks</p>	26/11/2023	<b>330</b>	<b>1</b>	<a href="#">View</a> <a href="#">Run</a> <a href="#">Edit</a> <a href="#">Delete</a>
	NOACS	Prescribing Safety Indicators	<p><b>DOAC patient not co-prescribed a PPI or H2RA to mitigate bleed risk</b></p> <p>Co-prescription of a PPI drug with DOACS reduces the risk of an upper GI bleed significantly. One study suggests that hospitalisation can be reduced from 4% to 2.8% by using PPIs. <a href="https://jamanetwork.com/journals/jama/fullarticle/2717474">https://jamanetwork.com/journals/jama/fullarticle/2717474</a></p>	26/11/2023	<b>6534</b>	<b>32</b>	<a href="#">View</a> <a href="#">Run</a> <a href="#">Edit</a> <a href="#">Delete</a>
	Cardiovascular	Prescribing Safety Indicators	<p><b>Glyceryl trinitrate is contraindicated in patients taking phosphodiesterase type 5 inhibitors (e.g. sildenafil, vardenafil, tadalafil)</b></p> <p>Never co-administer with: Consistent with its known effects on the nitric oxide/cyclic guanosine monophosphate (cGMP) pathway, phosphodiesterase type 5 inhibitors (e.g. sildenafil, vardenafil and tadalafil) have been shown to potentiate the hypotensive effects of nitrates (possibly resulting in collapse, unconsciousness and even death), and coadministration with glyceryl trinitrate is therefore contraindicated (see section 4.3).</p>	26/11/2023	<b>89</b>	<b>0</b>	<a href="#">View</a> <a href="#">Run</a> <a href="#">Edit</a> <a href="#">Delete</a>
	Other	Prescribing Safety Indicators	<p><b>Learning disability on antipsychotic and no psychosis read code</b></p> <p>Learning disability on antipsychotic and no psychosis read code. NICE guidance on Psychotropic medicines in people with learning disabilities whose behaviour challenges. Use NHSE STOMP guide (stopping over medication of people with learning disabilities) to consider alternative treatments. <a href="https://www.england.nhs.uk/learning-disabilities/stomp/">https://www.england.nhs.uk/learning-disabilities/stomp/</a></p>	26/11/2023	<b>279</b>	<b>0</b>	<a href="#">View</a> <a href="#">Run</a> <a href="#">Edit</a> <a href="#">Delete</a>

# What practice sees

	 MDI/dry powder combination:	Patients 65 <u>(Unreviewed 65)</u>	<a href="#">View Patient(s)</a>	Sun 26/11 11:23
	 Combined ACEI and ARB treatment:	Patients 11 <u>(Unreviewed 11)</u>	<a href="#">View Patient(s)</a>	Sun 26/11 11:23
	 Carbimazole can cause congenital malformations especially at higher doses:	Patients 9 <u>(Unreviewed 0)</u>	<a href="#">View Patient(s)</a>	Sun 26/11 11:22
	 Raised risk of certain skin cancers in long term hydrochlorothiazide use:	Patients 5 <u>(Unreviewed 1)</u>	<a href="#">View Patient(s)</a>	Sun 26/11 11:20
	 Zonisamide in females of child bearing age:	Patients 2 <u>(Unreviewed 0)</u>	<a href="#">View Patient(s)</a>	Sun 26/11 11:20
	 Severe hyperkalaemia $\geq 6.5$ mmol/L:	Patients 3 <u>(Unreviewed 3)</u>	<a href="#">View Patient(s)</a>	Sun 26/11 11:20
	 Warfarin in women of child bearing age not taking prescribed contraception:	Patients 7 <u>(Unreviewed 0)</u>	<a href="#">View Patient(s)</a>	Sun 26/11 11:18
	 Nicorandil in active ulceration:	Patients 1 <u>(Unreviewed 0)</u>	<a href="#">View Patient(s)</a>	Sun 26/11 11:16

# If you want access...

Contact Eclipse at [support@prescribingservices.org](mailto:support@prescribingservices.org)

Practice manager to send email giving consent for that person to access the practice data

Supply name, email address and mobile number (for PIN access)

Log in to <https://secure.nhspathways.org/> NHS Pathways

Or <https://www.eclipsesolutions.org/> for Eclipse alerts

Thank you!